Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ervebo

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Merck & Co to buy IO specialists Immune Design for $300m

US giant looks to next generation technology

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Merck puts prostate cancer firmly in Keytruda’s sights

Lynparza combination could open up huge new market

- PMLiVE

Analysts look beyond Keytruda in Merck’s future

CEO Frazier made to defend pipeline prospects

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links